Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | EVP, CSO and CMO | February 25, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 25, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,535 |
Reported balance
After 2021-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-25 · Grant · Acquired 64,361 · Balance 137,535 F1: These shares represent restricted stock units ("RSUs"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 9,361 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting. F2: Includes (i) 64,361 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (ii) 33,174 shares of common stock owned by the reporting person. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2031-02-25 | Direct | 139,000 |
Reported balance
After 2021-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-25 · Grant · Acquired 139,000 · Balance 139,000 F3: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 9,361 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting.
F2: Includes (i) 64,361 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (ii) 33,174 shares of common stock owned by the reporting person.
F3: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Mar 2, 2021 02:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 139,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000292 · e620327_4-mond.xml · derivative · entry 2 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 Underlying: Common Stock · 139,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 64,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-21-000292 · e620327_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,535 F1 · shares: These shares represent restricted stock units ("RSUs"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 9,361 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 64,361 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (ii) 33,174 shares of common stock owned by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 4,000 | $2.20 | $8,800.00 |
DisclosureSEC source: 0001193805-20-001129 · e619922_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,174 F1 · balance_after: Includes 40,000 RSUs granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 2,000 | $2.88 | $5,750.00 |
DisclosureSEC source: 0001193805-20-001003 · e619854_4-mond.xml · nonDerivative · entry 2 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,174 F1 · balance_after: Includes 40,000 RSUs granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $2.88 | $14,400.00 |
DisclosureSEC source: 0001193805-20-001003 · e619854_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,174 F1 · balance_after: Includes 40,000 RSUs granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:07 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000285 · e619419_4-mond.xml · derivative · entry 2 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-28 F3 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:07 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000285 · e619419_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,174 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 40,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 22,174 shares of common stock owned by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:16 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 4,285 | $3.50 | $14,997.50 |
DisclosureSEC source: 0001193805-20-000133 · e619335_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,174 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| May 17, 2019 Filed May 21, 2019 11:12 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 4,500 | $4.00 | $18,000.00 |
DisclosureSEC source: 0001193805-19-000522 · e618481_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,889 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 02:31 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001193805-19-000091 · e618165_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001193805-18-000190 · e617684_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:45 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 10,000 | $2.15 | $21,500.00 |
DisclosureSEC source: 0001193805-17-003449 · e617468_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,389 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 242,546 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001055 · e616262_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,546 Underlying: Common Stock · 242,546 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000276 · e615798_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · CSO/CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.